Correspondence Regarding "Delamanid For Rifampicin-Resistant Tuberculosis: A Retrospective Study From South Africa"

Erika Mohr-Holland,Anja Reuter,Jennifer Hughes,Johnny Daniels,Busisiwe Beko, Goodman Makhanda,Virginia De Avezedo,Yulene Kock,Helen Cox,Jennifer Furin,Laura Trivino Duran,Petros Isaakidis,Gabriella Ferlazzo

EUROPEAN RESPIRATORY JOURNAL（2020）

Cited 3|Views15

No score

Abstract

Delamanid (Dlm) containing regimens to treat RR-TB are effective, but more data on Dlm use is needed. Dlm remains an important treatment option in programmatic settings with high rates of HIV co-infection and in persons with limited treatment options.https://bit.ly/3cVLeUq

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined